
Alcon ALC
$ 81.19
0.07%
Annual report 2024
added 01-24-2026
Alcon General and Administrative Expenses 2011-2026 | ALC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Alcon
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 251 M | - | 2.8 B | 2.79 B | 2.6 B | 2.53 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 251 M | 2.19 B |
Quarterly General and Administrative Expenses Alcon
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 69 M | - | - | - | 62 M | - | - | - | 54 M | - | - | - | 49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 69 M | 49 M | 58.5 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M | ||
|
Baxter International
BAX
|
2.97 B | $ 19.93 | 0.99 % | $ 10.2 B | ||
|
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
8.79 M | $ 8.71 | 3.75 % | $ 176 M | ||
|
AtriCure
ATRC
|
291 M | $ 36.37 | -1.57 % | $ 1.71 B | ||
|
Repro Med Systems
KRMD
|
20.4 M | $ 5.37 | -1.56 % | $ 245 M | ||
|
Haemonetics Corporation
HAE
|
437 M | $ 65.87 | -0.15 % | $ 3.32 B | ||
|
electroCore
ECOR
|
27.2 M | $ 6.83 | -3.73 % | $ 37.7 K | ||
|
AngioDynamics
ANGO
|
42.1 M | $ 10.2 | 2.2 % | $ 417 M | ||
|
ICU Medical
ICUI
|
639 M | $ 149.04 | -0.66 % | $ 3.63 B | ||
|
InfuSystem Holdings
INFU
|
46.1 M | $ 8.14 | 1.12 % | $ 168 M | ||
|
The Cooper Companies
COO
|
1.63 B | $ 80.95 | 0.72 % | $ 16.1 B | ||
|
Masimo Corporation
MASI
|
744 M | $ 134.5 | -1.29 % | $ 7.17 B | ||
|
Harvard Bioscience
HBIO
|
22.8 M | $ 0.5 | -7.06 % | $ 21.2 M | ||
|
Glaukos Corporation
GKOS
|
224 M | $ 117.26 | -1.43 % | $ 5.68 B | ||
|
Merit Medical Systems
MMSI
|
400 M | $ 80.09 | -0.19 % | $ 4.66 B | ||
|
OraSure Technologies
OSUR
|
46.2 M | $ 2.78 | -0.54 % | $ 207 M | ||
|
Isoray
ISR
|
26.6 M | - | 0.03 % | $ 108 M | ||
|
iRhythm Technologies
IRTC
|
419 M | $ 150.09 | 0.74 % | $ 4.68 B | ||
|
LeMaitre Vascular
LMAT
|
36.3 M | $ 84.08 | 0.26 % | $ 1.89 B | ||
|
Intuitive Surgical
ISRG
|
2.14 B | $ 505.88 | -0.33 % | $ 180 B | ||
|
STERIS plc
STE
|
1.33 B | $ 261.25 | -0.23 % | $ 25.8 B | ||
|
NeuroMetrix
NURO
|
6.33 M | - | 5.05 % | $ 9.02 M | ||
|
Microbot Medical
MBOT
|
4.13 M | $ 1.84 | -1.34 % | $ 18.8 M | ||
|
Nephros
NEPH
|
8.91 M | $ 4.4 | 0.23 % | $ 45.7 M | ||
|
Utah Medical Products
UTMD
|
11 M | $ 60.16 | -2.42 % | $ 218 M | ||
|
Milestone Scientific
MLSS
|
12.3 M | $ 0.29 | -0.7 % | $ 23.1 M | ||
|
Envista Holdings Corporation
NVST
|
1.16 B | $ 23.07 | -1.28 % | $ 3.97 B | ||
|
Pro-Dex
PDEX
|
4.84 M | $ 38.84 | -1.43 % | $ 128 M | ||
|
Predictive Oncology
POAI
|
7.42 M | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
15.8 M | $ 13.69 | 0.48 % | $ 658 M | ||
|
Becton, Dickinson and Company
BDX
|
5.28 B | $ 201.67 | 0.29 % | $ 58 B | ||
|
Repligen Corporation
RGEN
|
219 M | $ 151.86 | -2.88 % | $ 8.46 M | ||
|
ResMed
RMD
|
739 M | $ 251.52 | -2.37 % | $ 36.7 B | ||
|
BioLife Solutions
BLFS
|
40.5 M | $ 22.08 | -2.21 % | $ 1.02 B | ||
|
Stereotaxis
STXS
|
14 M | $ 2.26 | -3.21 % | $ 182 M | ||
|
Retractable Technologies
RVP
|
13.6 M | $ 0.69 | 0.16 % | $ 20.7 M | ||
|
STAAR Surgical Company
STAA
|
89.9 M | $ 18.79 | -0.8 % | $ 923 M | ||
|
Teleflex Incorporated
TFX
|
995 M | $ 105.0 | -0.43 % | $ 4.92 B | ||
|
West Pharmaceutical Services
WST
|
338 M | $ 226.43 | -2.61 % | $ 16.5 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.6 B | $ 12.28 | 0.04 % | $ 2.5 B |